Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 4/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425828 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL6730565 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL3145889 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL13317630 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL8600119 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL3425832 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL14356311 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL3954465 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL5981862 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| Water SCHEMBL28110031 | 0.98 | SLC6A2 (0.43) | SLC6A2CA1CA2CA9TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605713-B1 | Contacting D-nucleic acids with a racemic mixture of the target molecule and allow for binding; producing L-nucleic acids; in vitro selection of DNA/RNA with high binding affinity and stability | FURSTE JENS PETER (DE) | 2003-08-12 | — | — | US | claimed |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | REATA PHARMACEUTICALS, INC (US) | 2023-11-28 | — | — | US | disclosed |
| CN-104142375-B | A kind ofly utilize mould metabolic product to set up finger-print and utilize the method for fingerprint identification mold species | WEIFANG ENTRY-EXIT INSPECTION AND QUARANTINE BUREAU OF PRC (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-104142375-A | Methods for constructing fingerprint by using mildew metabolites and authenticating mildew strains according to fingerprint | WEIFANG ENTRY EXIT INSPECTION AND QUARANTINE BUREAU OF P R C | 2014-11-12 | — | — | CN | disclosed |
| US-6605713-B1 | Contacting D-nucleic acids with a racemic mixture of the target molecule and allow for binding; producing L-nucleic acids; in vitro selection of DNA/RNA with high binding affinity and stability | FURSTE JENS PETER (DE) | 2003-08-12 | — | — | US | disclosed |
| CN-1113892-C | Process for preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine | UNIV OF GEORGIA RES FOUNDATION (US) | 2003-07-09 | — | — | CN | disclosed |
| EP-0934331-B1 | MIRROR-SYMMETRICAL SELECTION AND EVOLUTION OF NUCLEIC ACIDS | FUERSTE JENS PETER (DE) | 2002-11-27 | — | — | EP | disclosed |
| CN-1206012-A | Process for preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine | TNE UNIVERSITY OF GEORGIA RESE (US) | 1999-01-27 | — | — | CN | disclosed |
| EP-0434960-B1 | Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates | PHARMACIA SPA (IT) | 1996-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827664-B2 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway | HSPA2, HSP90AB2P, HSF1 | SLC6A2 2659/4885CA1 4529/4885CA2 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.